1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study in human breast cancer cell lines without human subjects.
What was done
Researchers investigated the mechanism by which 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] and four synthetic analogues (EB-1089, KH-1060, Ro 27-0574, and Ro 23-7553) inhibit cell proliferation in estrogen-responsive MCF-7 human breast cancer cells. They assessed estrogen receptor (ER) abundance via ligand binding assays and Western blots, measured ER mRNA levels and stability using cycloheximide and actinomycin D, analyzed ER gene transcription with nuclear run-on assays, and measured estrogen-induced downstream targets, including progesterone receptor and BRCA1 protein.
What was found
1,25(OH)2D3 and its analogues reduced ER levels in a dose-dependent manner. Antiproliferative activity strongly correlated with ER downregulation across the tested analogues (R2 = 0.98). ER mRNA levels decreased following treatment, an effect not prevented by cycloheximide. Actinomycin D experiments showed no difference in ER mRNA half-life between treated and control cells, whereas nuclear run-on assays confirmed a significant decrease in ER gene transcription by 17 hours of treatment. Pretreatment with 1,25(OH)2D3 also suppressed estradiol-induced stimulation of cell growth, progesterone receptor expression, and BRCA1 protein levels. Exact percentage changes or p-values were not reported in the abstract.
Why it matters
This study provides a direct transcriptional mechanism explaining how vitamin D metabolites counter estrogen-driven growth in ER-positive breast cancer cells, supporting the therapeutic rationale for vitamin D analogues in breast cancer management.
Limits
The study is restricted to an in vitro model using a single human breast cancer cell line (MCF-7), precluding direct conclusions about clinical efficacy, in vivo pharmacokinetics, or tumor heterogeneity in human patients. Specific quantitative effect sizes and statistical variance metrics were omitted from the abstract.
Cited by
- supports Vitamin D decreases estrogen receptor sensitivity and expression.